Description

Tepotinib 225mg Tablets

Tepotinib 225mg Tablets represent a highly specialized, targeted therapy for the treatment of non-small cell lung cancer (NSCLC) driven by specific genetic alterations. Pharmacologically, the medication functions as a potent and highly selective Type Ib inhibitor of the mesenchymal-epithelial transition (MET) factor receptor tyrosine kinase.

In healthy cells, the MET pathway regulates cell growth, survival, and migration. However, in cancers harboring MET exon 14 skipping alterations, the regulatory region of the receptor is lost, leading to decreased degradation and continuous, uncontrolled signaling. Tepotinib 225mg Tablets work by binding to the intracellular ATP-binding pocket of the MET receptor. This binding inhibits the autophosphorylation of MET and blocks the downstream signaling cascades (such as PI3K/AKT and RAS/MAPK) that are essential for the proliferation and survival of the tumor cells. By shutting down this hyperactive pathway, the drug induces tumor shrinkage and halts disease progression.

Indications / Uses of Tepotinib 225mg Tablets

Tepotinib 225mg Tablets are indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). The prescription is strictly guided by the genetic profile of the tumor. Common indications include:

• MET Exon 14 Skipping Alterations: Indicated specifically for patients whose tumors harbor MET exon 14 skipping mutations, as detected by an FDA-approved test (using either plasma “liquid biopsy” or tissue biopsy). This mutation acts as an oncogenic driver in approximately 3-4% of NSCLC cases.
• Metastatic Disease: Used in the setting of advanced cancer that has spread to other parts of the body, providing a targeted option where chemotherapy or immunotherapy might be less effective.
• Systemic Therapy: It serves as a systemic treatment option for both treatment-naïve patients (first-line) and those who have previously received other systemic therapies.

Key Features

• High Selectivity: Designed to specifically inhibit the MET receptor with high potency while sparing other kinases, potentially reducing the risk of off-target side effects.
• Oral Administration: The tablet formulation allows for convenient oral dosing. The standard regimen typically involves taking two 225mg tablets once daily.
• Once-Daily Dosing: The medication’s pharmacokinetic profile supports once-daily administration, which helps maintain consistent therapeutic drug levels and simplifies patient adherence.
• Dual Biopsy Applicability: Efficacy has been demonstrated in patients identified via both liquid biopsy (blood test) and tissue biopsy, offering flexibility in diagnostic testing.

Storage for Tepotinib 225mg Tablets

To ensure the stability and safety of Tepotinib 225mg Tablets, proper storage conditions are essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the tablets in their original container to protect them from moisture. The bottle usually contains a desiccant; do not remove it. Keep the container tightly closed after every use and store it in a dry, secure place, out of the reach and sight of children and pets.

Important Note on Tepotinib 225mg Tablets

Treatment with Tepotinib 225mg Tablets requires careful management of specific adverse reactions. Interstitial Lung Disease (ILD) or Pneumonitis is a rare but serious and potentially fatal side effect. Patients should be monitored for new or worsening respiratory symptoms (e.g., cough, shortness of breath, fever) and treatment may need to be permanently discontinued if ILD is confirmed.

Peripheral Edema (swelling of the extremities) is the most common side effect. It can be managed with limb elevation, compression stockings, or diuretics, but may require dose interruption or reduction if severe.

Hepatotoxicity (liver injury) can occur; therefore, liver function tests (ALT, AST, bilirubin) should be monitored prior to initiation and regularly during treatment.

The medication should be taken with food to ensure optimal absorption. It can cause fetal harm and is not recommended for pregnant women. Females of reproductive potential and males with female partners should use effective contraception during treatment and for one week after the final dose. Always consult your oncologist about any new symptoms or other medications you are taking.